SCHEMBL5386444

SCHEMBL5386444

COC(=O)c1cc(S(=O)(=O)Nc2ccc(-c3ccc(OC(F)(F)F)cc3)cc2)ccc1C(C)C

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PLAU P00749 9/20 0.54
PLAT P00750 2/20 0.52
SMN1; SMN2 Q16637 1/20 0.50
KIF11 P52732 1/20 0.50
HDAC1 Q13547 3/20 0.48
HDAC8 Q9BY41 3/20 0.48
HDAC3 O15379 2/20 0.48
HDAC4 P56524 2/20 0.48
HDAC7 Q8WUI4 2/20 0.48
HDAC2 Q92769 2/20 0.48
HDAC10 Q969S8 2/20 0.48
HDAC11 Q96DB2 2/20 0.48
HDAC6 Q9UBN7 2/20 0.48
HDAC9 Q9UKV0 2/20 0.48
HDAC5 Q9UQL6 2/20 0.48
MAPT P10636 2/20 0.48
LMNA P02545 1/20 0.48
TP53 P04637 1/20 0.48
POLB P06746 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5376594 0.92 POLB (0.51) PLAUSMN1; SMN2KIF11HDAC1HDAC8
SCHEMBL5368389 0.86 POLB (0.60) PLAUPLATSMN1; SMN2KIF11HDAC1
SCHEMBL5388023 0.86 HDAC1 (0.46) PLAUPLATSMN1; SMN2HDAC1HDAC8
SCHEMBL5378584 0.85 PTPN1 (0.61) MAPT
SCHEMBL5370673 0.84 PLAU (0.52) PLAUPLATSMN1; SMN2KIF11HDAC1
SCHEMBL5368290 0.84 PLAU (0.53) PLAUPLATSMN1; SMN2MAPTLMNA
SCHEMBL5378701 0.81 KIF11 (0.52) PLAUSMN1; SMN2KIF11HDAC1HDAC8
SCHEMBL5377005 0.81 HDAC3 (0.49) PLAUPLATSMN1; SMN2HDAC1HDAC8
SCHEMBL5320408 0.80 POLB (0.69) SMN1; SMN2KIF11HDAC1HDAC8HDAC3
SCHEMBL15055587 0.80 PFKFB3 (0.51) PLAUPLATSMN1; SMN2KIF11HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7262318-B2 Substituted heteroaryl- and phenylsulfamoyl compounds PFIZER, INC. (US) 2007-08-28 US disclosed
EP-1725524-A1 SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS Pfizer Products Incorporated (US) 2006-11-29 EP disclosed
US-20060258723-A1 Substituted Heteroaryl- and Phenylsulfamoyl Compounds PFIZER INC 2006-11-16 US disclosed
US-20050228015-A1 Substituted heteroaryl- and phenylsulfamoyl compounds PFIZER INC 2005-10-13 US disclosed
WO-2005092845-A1 SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS PFIZER PRODUCTS INC. (US) 2005-10-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050228015-A1 Substituted heteroaryl- and phenylsulfamoyl compounds PPARA, PPARG, PPARD PLAU 3190/4885PLAT 317/4885SMN1; SMN2 3404/4885
US-20060258723-A1 Substituted Heteroaryl- and Phenylsulfamoyl Compounds PPARG, PPARA, PPARD PLAU 3215/4885PLAT 405/4885SMN1; SMN2 3296/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.